Latest tumor Stories

Fat progenitor cells may contribute to cancer growth by fortifying the vessels that provide needed blood to tumors, according to preclinical research findings by investigators at The University of Texas Health Science Center at Houston (UTHealth). The results were reported in Cancer Research, a journal of the American Association for Cancer Research. Studies of groups of people have demonstrated a link between obesity and certain cancers; however, the physiological causes have not been...

After leukaemia and brain tumors, neuroblastoma is the most common form of cancer to affect children. A thesis from the Sahlgrenska Academy, University of Gothenburg, Sweden, has studied a DNA method which is now used for all cases of neuroblastoma in Sweden, and which has led to more effective treatment at individual level. Neuroblastoma affects around 20 children each year, most of them under the age of two. This form of cancer, which affects the peripheral nervous system, is...

TAICHUNG, Taiwan, Oct. 15, 2012 /PRNewswire/ -- Doctors at the Cheng Ching General Hospital here have begun treating liver cancer with image-guided radiosurgery using a new TrueBeam(TM) STx system from Varian Medical Systems (NYSE:VAR). The hospital has developed a program for treating hepatocellular carcinoma (HCC), a common type of liver cancer that is widespread in Asia. "With TrueBeam STx, we can generate images of the tumor during the treatment, and use them to adapt the...

How tumors exploit microflora and immune cells to fuel growth Researchers at the University of California, San Diego School of Medicine report the discovery of microbial–dependent mechanisms through which some cancers mount an inflammatory response that fuels their development and growth. The findings are published in the October 3, 2012 Advanced Online Edition of Nature. The association between chronic inflammation and tumor development has long been known from the early work of...

MADISON, Wis., Oct. 3, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that an oral presentation on research conducted by Jamey Weichert, Ph.D., Lance Hall, M.D., Anne M. Traynor, M.D., Glenn Liu, M.D. and their colleagues is being made by Dr. Weichert at the Imaging in 2020 Conference taking place September 30 to October 4, 2012 in Jackson Hole, Wyoming....

NEW YORK, Sept. 28, 2012 /PRNewswire/ -- There are two common dilemmas in the treatment of cancer today: the first is that many therapies, including chemotherapies and radiation can debilitate healthy cells, to the point of killing the person before defeating the cancer. The second problem is that many cancer cells, responding to a prevention drug, can quickly mutate to become immune and more resilient. Recent advances in circulating tumor cell technology (CTC) however, headed by...

WICHITA, Kan., Sept. 25, 2012 /PRNewswire-USNewswire/ -- Inflammatory responses play roles at different stages of tumor development, including initiation, promotion, malignant conversion, invasion, and metastasis. The 'inflammation- cancer' connection is not restricted to increased risk for a subset of tumors. An inflammatory component is present in the microenvironment of most neoplastic tissues. High inflammatory levels appear to indicate increased cancer risk and poorer...

MGH study identifies components responsible for therapy-blocking solid stress, suggests therapeutic strategies It's a high-pressure environment within solid tumors. Abnormal blood and lymphatic vessels cause fluids to accumulate, and the uncontrolled proliferation of cancer cells within limited space leads to the buildup of what is called solid stress. Both types of pressure can interfere with the effectiveness of anticancer treatments, but while strategies have been developed that reduce...

Decorin, a well-studied protein, induces tumor suppressor genes in microenvironment to stop metastasis, Thomas Jefferson University researchers say A natural substance found in the surrounding tissue of a tumor may be a promising weapon to stop triple negative breast cancer from metastasizing. A preclinical study published in PLOS ONE September 19 by Thomas Jefferson University researchers found that decorin, a well-studied protein known to help halt tumor growth, induces a series of...

CAMBRIDGE, Mass., Sept. 18, 2012 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that research evaluating two novel compounds for advanced cancers, including breast, ovarian, gastric and bladder, will be presented at the ESMO 2012 Congress (European Society for Medical Oncology ), Sept. 28 - Oct. 2 in Vienna, Austria. The medicines are some of the first therapies developed using Merrimack's proprietary scientific approach - Network Biology - focusing...